These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22033461)

  • 1. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry.
    Kalesh KA; Liu K; Yao SQ
    Org Biomol Chem; 2009 Dec; 7(24):5129-36. PubMed ID: 20024108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2 nanoparticle deposited capillary column.
    Lü S; Luo Q; Li X; Wu J; Liu J; Xiong S; Feng YQ; Wang F
    Analyst; 2010 Nov; 135(11):2858-63. PubMed ID: 20835477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
    Crespan E; Radi M; Zanoli S; Schenone S; Botta M; Maga G
    Bioorg Med Chem; 2010 Jun; 18(11):3999-4008. PubMed ID: 20451394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular mechanics model for imatinib and imatinib:kinase binding.
    Aleksandrov A; Simonson T
    J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
    Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
    Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
    ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
    Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
    Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
    [No Abstract]   [Full Text] [Related]  

  • 15. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors.
    Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y
    Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
    El-Deeb IM; Lee SH
    Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.